On the other hand, the elevated AD risk of ε4 carriers may be related with higher tau load, although this also appears to be primarily mediated by the strong APOE-ε4 effect on increased Aβ pathology, except in the ERC where Aβ-independent effects were significant. Here, MAPT is linked to Alzheimer disease.